Journal article icon

Journal article

Head-to-head comparison of the RMI and ADNEX models to estimate the risk of ovarian malignancy: a systematic review and meta-analysis of external validation studies

Abstract:
Objectives: Assessment of Different NEoplasias in the adneXa (ADNEX) and Risk of Malignancy Index (RMI) are models that estimate the risk of malignancy in ovarian masses based on clinical and ultrasound information. The aim is to perform a meta-analysis of studies that compared the performance of the two models in the same patients (‘head-to-head comparison’). Design: Systematic review and meta-analysis. Data sources: Systematic literature search from publication of ADNEX model (15/10/2014) up to 31/07/2024 in Embase, Web of Science, Scopus, Medline (via PubMed) and EuropePMC. Eligibility criteria for selecting studies: We included all studies that externally validated the performance of ADNEX (with or without CA125) and RMI on the same data. Data extraction and synthesis: Two independent reviewers extracted data using a standardised extraction sheet. We assessed risk of bias using PROBAST. We performed random effects meta-analysis of the area under the receiver operating characteristic curve (AUC), sensitivity, specificity and clinical utility (net benefit, relative utility and probability of being useful in a hypothetical new centre) at thresholds commonly used clinically (10% risk of malignancy for ADNEX, 200 for RMI). Results: We included 11 studies comprising 8271 tumours. Most studies were at high risk of bias. The summary AUC to distinguish benign from malignant tumours in operated patients for ADNEX with CA125 was 0.92 (95% CI 0.90 to 0.94) and for RMI it was 0.85 (0.81 to 0.89). Sensitivity and specificity for ADNEX with CA125 were 0.93 (0.90 to 0.96) and 0.77 (0.71 to 0.81) and for RMI, they were 0.61 (0.56 to 0.67) and 0.92 (0.89 to 0.94). The probability of the test being useful in a hypothetical new centre in operated patients was 96% for ADNEX with CA125 and 15% for RMI at the selected thresholds. Conclusions: ADNEX has better discrimination and clinical utility than RMI.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1136/bmjopen-2025-104141

Authors

More by this author
Role:
Author
ORCID:
0000-0001-8020-0210
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Sub department:
Centre for Statistics in Medicine
Oxford college:
Nuffield College
Role:
Author
ORCID:
0000-0002-0989-0623
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Sub department:
Centre for Statistics in Medicine
Oxford college:
Nuffield College
Role:
Author
ORCID:
0000-0002-2772-2316


More from this funder
Funder identifier:
https://ror.org/05f950310
More from this funder
Funder identifier:
https://ror.org/03qtxy027
More from this funder
Funder identifier:
https://ror.org/054225q67


Publisher:
BMJ Publishing Group
Journal:
BMJ Open More from this journal
Volume:
15
Issue:
10
Article number:
bmjopen-2025-104141
Publication date:
2025-10-07
Acceptance date:
2025-08-04
DOI:
EISSN:
2044-6055
ISSN:
2044-6055


Language:
English
Keywords:
Pubs id:
2301184
Local pid:
pubs:2301184
Source identifiers:
3366554
Deposit date:
2025-10-13
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP